Insider trades
Peter Evan Harwin, Director of Spyre Therapeutics SYRE, has filed 13 purchases and 2 sales on the open market. Over the past 12 months that comes to a net sale of $505.9M. The latest trade was on 06/23.
Peter Evan Harwin
Director
- Company
- Spyre Therapeutics SYRE
- First filing
- 23/06/08
- Trades
- 89 trades
- Buys / sales
- 13 / 2
- 12-month net buying
- −$505.9M
- Last trade
- 06/23
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale | 06/23 | 06/23 | 4,684,781 sh | $85.31 | $399,658,667.11 | −100.0% | |
Zenas BioPharmaZBIO | Open-market buy | 03/31 | 04/01 | 150,000 sh | $20.00 | $3,000,000 | +6.8% |
| Open-market sale | 01/22 | 01/22 | 1,750,000 sh | $76.30 | $133,525,000 | −85.4% | |
| Open-market buy | 25/12/04 | 25/12/08 | 1,360,000 sh | $13.41 | $18,237,600 | +98.0% | |
Zenas BioPharmaZBIO | Open-market buy | 25/10/07 | 25/10/09 | 316,219 sh | $19.00 | $6,008,161 | +16.7% |
Zenas BioPharmaZBIO | Open-market buyAmendment | 24/09/16 | 24/09/17 | 300,000 sh | $17.00 | $5,100,000 | +18.8% |
Zenas BioPharmaZBIO | Open-market buy | 24/09/16 | 24/09/16 | 300,000 sh | $17.00 | $5,100,000 | +23.0% |
| Open-market buy | 23/09/29 | 23/10/03 | 24,670 sh | $13.63 | $336,252.1 | +1.3% | |
| Open-market buy | 23/09/26 | 23/09/28 | 30,000 sh | $13.15 | $394,500 | +1.6% | |
| Open-market buy | 23/09/19 | 23/09/21 | 30,000 sh | $13.20 | $396,000 | +1.6% | |
DNTH | Open-market buy | 23/09/12–23/09/13 | 23/09/13 | 24,254 sh2 trades | $11.20avg. | $271,679.87 | +1.3% |
| Open-market buy | 23/07/13 | 23/07/17 | 2,941,176 sh3 trades | $17.00avg. | $49,999,992 | No record |
